TEL AVIV, Israel, May 23, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Jonathan Rubin, Chief Medical Officer of Alcobra, will provide an oral presentation on Metadoxine Extended Release (MDX) clinical studies, as well as a poster presentation with new pre-clinical data at the Fragile X and Autism-Related Disorders Gordon Research Conference, being held June 1-6, 2014 at the Mount Snow Resort in West Dover, Vermont.
Oral Presentation
| Date: | June 3, 2014 |
| Session: | Clinical Trials of Targeted Treatments |
| Time: | 8:50pm - 9:20pm |
| Title: | The Development of Metadoxine Extended Release (MDX), a Novel GABA/Glutamate Modulating Agent, for Cognitive Impairment in Fragile X |
Poster Presentation
| Date: | June 2, 2014 |
| Time: | 4pm Eastern |
| Title: | Metadoxine Effects in the Fmr1 Knockout Mouse: A Novel Pharmacologic Approach to Treating Fragile X Syndrome |
About the Fragile X and Autism-Related Disorders Gordon Research Conference
This conference will bring together leading scientists and clinicians in the Fragile X (FXS), Autism Spectrum Disorders (ASD), and Neurodevelopmental disorders (NDD), particularly those working on forms of ASD/NDD with dysfunctions in molecular pathways that overlap those implicated in FXS. Topics will include the latest developments in genetics of ASDs and related diseases, FMRP function and its regulation, the overlap between the diseases at the molecular and genetic level, model system characterizations, dendritic spine dynamics and synaptic plasticity studies, outcome measures, and translation to treatment trials in humans with FXS and ASD/NDD. The conference is expected to accelerate the pace of bench-to-bedside translational research to bring important targeted treatments to individuals with FXS and ASD-related disorders. For further details, including the agenda, go to
http://www.grc.org/programs.aspx?year=2014&program=fragilex.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder, and is enrolling patients in a Phase III study for this indication in adults. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.